Cardiovascular Disease in 2023: Coronary Syndrome, Heart Failure and Structural Heart Disease

Dear Colleagues,

Despite the development of new therapeutic strategies, cardiovascular disease remains the leading cause of death worldwide.

In recent years, the number of treatment options for patients with valvular heart disease has increased significantly with the development of innovative percutaneous options. While TAVI has become the standard procedure for patients with moderate- to high-risk aortic stenosis, the treatment of mitral and tricuspid valve disease has proven to be highly challenging. Due to the different aetiologies of valve dysfunction and the complex architecture of the atrioventricular valves, the interventional treatment of the mitral and tricuspid valves requires an individualized approach.

The largest field of interventional cardiology is coronary revascularization. In recent years, new devices and concepts for invasive imaging and physiological assessment have been developed to reduce the number of existing challenges.

Despite these advancements, the mortality and morbidity rates in people with heart failure remain high. In recent years, new pharmacological and non-pharmacological therapeutic options for people with heart failure have been developed.

This Topic presents new therapeutic options to improve cardiovascular disease therapies in structural heart interventions, coronary revascularization and heart failure.

Dr. Saverio Muscoli
Dr. Rafael Vidal-Perez
Topic Editors